Core Viewpoint - The company,希教国际控股, proposes to increase its authorized share capital to enhance fundraising flexibility for future business growth [1] Group 1: Share Capital Structure - The current authorized share capital of the company is $100,000, divided into 10 billion shares, with approximately 8.674 billion shares issued [1] - The proposed increase in authorized share capital will raise it to $200,000, divided into 20 billion shares, assuming no shares are issued or repurchased until the annual general meeting on February 27, 2026 [1] - After the proposed increase, approximately 8.674 billion shares will remain issued, and 11.326 billion shares will be authorized but unissued [1]

Core Viewpoint - The company, Xuejiao International Holdings (01765), announced a proposal to increase its authorized share capital to enhance fundraising flexibility for future business growth [1] Group 1: Share Capital Details - The current authorized share capital of the company is $100,000, divided into 10 billion shares, with approximately 8.674 billion shares issued [1] - The proposed increase in authorized share capital will raise it to $200,000, divided into 20 billion shares, assuming no shares are issued or repurchased until the annual general meeting on February 27, 2026 [1] - After the proposed increase, approximately 8.674 billion shares will remain issued, with 11.326 billion shares being authorized but unissued [1]

Core Viewpoint - The company, Xuejiao International Holdings (01765.HK), announced a proposal to increase its authorized share capital to enhance fundraising flexibility and promote future business growth [1] Group 1: Company Structure - The current authorized share capital of the company is $100,000, divided into 10,000,000,000 shares, of which 8,673,936,140 shares are issued [1] - The proposed increase in authorized share capital will allow for the issuance of new shares that will rank equally with existing shares in all respects [1] Group 2: Shareholder Approval - The proposal to increase the authorized share capital is subject to approval by the company's shareholders at the annual general meeting through an ordinary resolution [1]

Group 1 - The company proposes to increase its authorized share capital from HKD 50 million (5 billion shares) to HKD 400 million (40 billion shares) by issuing an additional 3.5 billion shares with a par value of HKD 0.1 each [1] - The increase in authorized share capital will take effect upon approval by shareholders at a special general meeting [1] Group 2 - The board recommends a rights issue where shareholders will receive 4 new shares for every 1 existing share held, at a subscription price of HKD 0.105 per share, representing a discount of approximately 42.86% [2] - The rights issue aims to raise up to approximately HKD 121.6 million, with a net estimated amount not exceeding HKD 62.5 million after expenses [2] - The proceeds will be allocated as follows: approximately HKD 41.2 million for repaying overdue bank loans and interest, about HKD 13.1 million for repaying shareholder loan balances, around HKD 7.7 million for settling trade and other payables, and the remaining HKD 0.5 million for general operational expenses [2]

Core Viewpoint - Hong Kong Communications International Holdings (00248) proposes a rights issue to raise up to approximately HKD 21.8 million by offering 77.83 million shares at a subscription price of HKD 0.28 per share, which represents a discount of about 25.5% from the adjusted closing price of HKD 0.376 per share [1][2]. Group 1: Rights Issue Details - The rights issue is based on a ratio of 1 share for every 2 existing shares held, and the shares to be issued will represent approximately 50.0% of the total issued shares post-consolidation and about 33.3% of the enlarged issued shares [1]. - The maximum gross proceeds from the rights issue, after offsetting approximately HKD 11.5 million owed to a shareholder, is expected to be around HKD 10.3 million, with a net amount of approximately HKD 9.4 million after expenses [2]. - The net proceeds will primarily be used to repay bank loans (approximately HKD 8.5 million or 90% of the net proceeds) and the remaining HKD 0.9 million (10% of the net proceeds) will be allocated for general working capital [2]. Group 2: Share Consolidation Proposal - The board proposes to increase the authorized share capital from HKD 20 million (20 billion existing shares) to HKD 40 million (40 billion shares) pending shareholder approval [3]. - A share consolidation is also proposed, where every 8 existing shares will be consolidated into 1 share, changing the nominal value from HKD 0.01 to HKD 0.08 per consolidated share, effective after shareholder approval [3]. - Following the consolidation, the trading unit on the Stock Exchange will change from 4,000 existing shares to 10,000 consolidated shares [3]. Group 3: Share Value Implications - Based on the current closing price of HKD 0.047 per existing share, the value of a trading unit of 4,000 existing shares is HKD 188, while the estimated value of a trading unit of 10,000 consolidated shares would be HKD 3,760 post-consolidation [4].

Group 1 - The company proposes to increase its authorized share capital from HKD 50 million (split into 1 billion shares) to HKD 100 million (split into 2 billion shares) by adding an additional 1 billion unissued shares, subject to approval at a special general meeting [1] - Following the increase in authorized share capital, the company plans to conduct a rights issue at a subscription price of HKD 0.08 per share, offering 1 share for every share held as of the record date, aiming to issue between 560 million and 641 million shares to raise at least approximately HKD 44.82 million before expenses [1] Group 2 - The estimated net proceeds from the rights issue will be at least approximately HKD 40.82 million and not exceeding approximately HKD 47.28 million, depending on the exercise of outstanding share options [2] - The company intends to use the net proceeds for several purposes, including: (i) developing existing pharmaceutical wholesale and distribution business, as well as dialysis treatment and consulting services, and potential investments in the healthcare sector; (ii) settling trade and other payables of approximately HKD 5 million and repaying a director's loan and accrued interest of approximately HKD 8.5 million; (iii) general working capital, including salaries, rent, professional fees, and other corporate expenses [2]

Group 1 - The company proposes to increase its authorized share capital from HKD 50 million (split into 1 billion shares) to HKD 100 million (split into 2 billion shares) by issuing an additional 1 billion unissued shares, subject to approval at a special shareholders' meeting [1] - Following the increase in authorized share capital, the company plans to conduct a rights issue at a subscription price of HKD 0.08 per share, offering 560 million to 641 million shares to raise at least approximately HKD 44.82 million before expenses [1] - The estimated net proceeds from the rights issue will be at least approximately HKD 40.82 million, assuming no changes in the number of shares issued prior to the record date [2] Group 2 - The company intends to use the net proceeds from the rights issue for several purposes, including the development of existing pharmaceutical wholesale and distribution businesses, as well as dialysis treatment and consulting services [2] - Part of the proceeds will be allocated to settle trade and other payables of approximately HKD 5 million and to repay a director's loan and accrued interest of approximately HKD 8.5 million [2] - The remaining funds will be utilized for general working capital, which includes but is not limited to salaries, rent expenses, professional fees, and other corporate expenses [2]

Core Viewpoint - China Silver Group (00815) proposes to increase its authorized share capital from HKD 30 million (30 billion shares) to HKD 50 million (50 billion shares) by adding 2 billion shares, allowing the new shares to have equal status with existing shares [1] Summary by Sections - **Share Capital Increase** - The board of directors recommends the issuance of 2 billion additional shares to enhance the company's authorized share capital [1] - The current issued shares stand at 2.954 billion, with 45.6624 million shares being authorized but unissued [1] - **Strategic Rationale** - The increase in authorized share capital aims to provide flexibility for future fundraising opportunities and to support the company's business plans and development [1]

Core Viewpoint - China Silver Group (00815) proposes to increase its authorized share capital from HKD 30 million (30 billion shares) to HKD 50 million (50 billion shares) by adding 2 billion shares, which will rank equally with existing shares after issuance [1] Group 1 - The board of directors believes that increasing the authorized share capital aligns with the overall interests of the company and its shareholders [1] - As of the announcement date, 2.954 billion shares have been issued, with 45.6624 million shares being authorized but unissued [1] - The increase in authorized share capital aims to provide flexibility for future fundraising opportunities and to support the company's business plans and development [1]

Core Viewpoint - China Silver Group (00815.HK) proposes to increase its authorized share capital from HKD 30 million (3 billion shares) to HKD 50 million (5 billion shares) by adding 2 billion shares, which will rank equally with existing shares after issuance [1] Group 1 - The board believes that increasing the authorized share capital will provide flexibility for future fundraising opportunities and support the company's business plans and development [1] - As of the announcement date, there are 2,954,337,559 shares issued, with 45,662,441 shares being authorized but unissued [1] - The proposed increase in share capital is considered to be in the overall interest of the company and its shareholders [1]